Skip to main content

Advertisement

Table 2 Cost-effectiveness analyses comparing IMRT, SBRT and PBT for localized prostate cancer treatment

From: Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review

Study (authors, year) Target population risk group Time horizon/cycle length Interventions compared Perspective/country Data sources Discount rate for costs and outcomes Model type/type of evaluation/sensitivity analysis
Effectiveness data Cost data/year
Parthan et al. (2012) [18] 65-year-old men with localized prostate cancer Lifetime/not reported SBRT vs. IMRT vs. PBT 3rd party Medicare payer and societal perspective/US Published sources, meta-analytical techniques Medicare rates, Bureau of Labour Statistic, literature sources, Red Book/2011 Costs and utilities discounted at 3.0% annually Markov model/cost-utility analysis/one-way deterministic and probabilistic sensitivity analysis
Hodges et al. (2012) [19] 70-year-old low-to intermediate-risk patient with confined prostate cancer 10 years/1 year IMRT vs SBRT 3rd party medicare payer perspective/US Literature sources Literature sources, medicare allowable costs, ambulatory payment classification/2010 Costs and utilities were discounted at a rate of 3% per year Markov model/cost-utility analysis/probabilistic sensitivity analysis
Sher et al. (2014) [20] 65-year-old men with low-risk prostate cancer Lifetime/4 months IMRT vs. robotic and non-robotic SBRT 3rd party medicare payer perspective/US Literature sources Medicare payment schedule for hospital-based practice/2012   Markov model/cost-utility analysis/one-way deterministic and probabilistic sensitivity analysis
Lundkvist et al. (2005) [21] Theoretical cohort age: 65-year Lifetime IMRT vs PBT Societal Sweden Literature sources Literature sources Costs and effects were discounted with 3% annually. Markov model cost-utility analysis
Konski et al. (2007) [22] Men aged 60 or 70 years old with intermediate-risk prostate cancer NA IMRT vs PBT payer US medicare literature literature and from patient interviews Costs and effects were discounted with 3% annually Markov model